| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Common variants at 19p13 are associated with susceptibility to ovarian cancer.
|
Nat Genet
|
2010
|
4.51
|
|
2
|
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24.
|
Nat Genet
|
2010
|
3.86
|
|
3
|
Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning.
|
J Clin Oncol
|
2011
|
3.69
|
|
4
|
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
|
J Clin Oncol
|
2008
|
2.66
|
|
5
|
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.
|
Lancet Oncol
|
2011
|
2.50
|
|
6
|
Treatment of breast cancer during pregnancy: an observational study.
|
Lancet Oncol
|
2012
|
2.38
|
|
7
|
Genome-wide association study identifies a common variant associated with risk of endometrial cancer.
|
Nat Genet
|
2011
|
1.84
|
|
8
|
Laparoscopy-assisted vaginal hysterectomy compared with abdominal hysterectomy in clinical stage I endometrial cancer: safety, recurrence, and long-term outcome.
|
Am J Obstet Gynecol
|
2007
|
1.80
|
|
9
|
Endometriosis and the development of malignant tumours of the pelvis. A review of literature.
|
Best Pract Res Clin Obstet Gynaecol
|
2004
|
1.66
|
|
10
|
Ovarian cancer.
|
Crit Rev Oncol Hematol
|
2006
|
1.64
|
|
11
|
Pseudomyxoma peritonei associated with a mucinous ovarian tumor arising from a mature cystic teratoma. A case report.
|
Int J Gynecol Pathol
|
2006
|
1.40
|
|
12
|
Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients.
|
Hum Brain Mapp
|
2011
|
1.31
|
|
13
|
Pathology and physiopathology of adenomyosis.
|
Best Pract Res Clin Obstet Gynaecol
|
2006
|
1.29
|
|
14
|
The classification of a uterine sarcoma as 'high-grade endometrial stromal sarcoma' should be abandoned.
|
Gynecol Oncol
|
2004
|
1.29
|
|
15
|
Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging.
|
Breast Cancer Res Treat
|
2006
|
1.26
|
|
16
|
Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer.
|
Clin Cancer Res
|
2011
|
1.19
|
|
17
|
Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.
|
Eur J Cancer
|
2013
|
1.17
|
|
18
|
Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?
|
J Clin Oncol
|
2008
|
1.17
|
|
19
|
Management of borderline ovarian neoplasms.
|
J Clin Oncol
|
2007
|
1.15
|
|
20
|
Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT.
|
Eur Radiol
|
2013
|
1.09
|
|
21
|
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.
|
Int J Gynecol Cancer
|
2016
|
1.06
|
|
22
|
Chemotherapy for recurrent cervical cancer.
|
Gynecol Oncol
|
2007
|
1.03
|
|
23
|
Genome-wide association study identifies a possible susceptibility locus for endometrial cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2012
|
1.02
|
|
24
|
Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses.
|
Eur J Cancer
|
2012
|
0.99
|
|
25
|
Progesterone receptor gene variants and risk of endometrial cancer.
|
Carcinogenesis
|
2010
|
0.98
|
|
26
|
Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis.
|
J Clin Oncol
|
2010
|
0.98
|
|
27
|
Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.
|
Breast Cancer Res Treat
|
2005
|
0.97
|
|
28
|
Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.
|
Breast Cancer Res Treat
|
2008
|
0.97
|
|
29
|
Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?
|
Gynecol Oncol
|
2012
|
0.95
|
|
30
|
Robotic retroperitoneal lower para-aortic lymphadenectomy in cervical carcinoma: first report on the technique used in 5 patients.
|
Acta Obstet Gynecol Scand
|
2008
|
0.92
|
|
31
|
Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy.
|
Cancer Immunol Immunother
|
2014
|
0.92
|
|
32
|
Viable cervical pregnancy with levonorgestrel containing intrauterine device, treated successfully with methotrexate and mifepristone.
|
Eur J Obstet Gynecol Reprod Biol
|
2005
|
0.90
|
|
33
|
Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk.
|
Hum Genet
|
2014
|
0.89
|
|
34
|
Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view.
|
Oncologist
|
2008
|
0.89
|
|
35
|
Sexual, psychological, and relational functioning in women after surgical treatment for vulvar malignancy: a literature review.
|
J Sex Med
|
2011
|
0.88
|
|
36
|
Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth.
|
J Clin Invest
|
2015
|
0.87
|
|
37
|
Progesterone inhibits epithelial-to-mesenchymal transition in endometrial cancer.
|
PLoS One
|
2012
|
0.87
|
|
38
|
Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer.
|
Mol Cancer
|
2014
|
0.87
|
|
39
|
No association between FTO or HHEX and endometrial cancer risk.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
0.87
|
|
40
|
Screening for uterine tumours.
|
Best Pract Res Clin Obstet Gynaecol
|
2011
|
0.87
|
|
41
|
Expression profiling to predict the clinical behaviour of ovarian cancer fails independent evaluation.
|
BMC Cancer
|
2008
|
0.86
|
|
42
|
Laparoscopic hysterectomy for early endometrial cancer.
|
Lancet Oncol
|
2010
|
0.86
|
|
43
|
Clinical recommendation on fertility preservation in borderline ovarian neoplasm: ovarian stimulation and oocyte retrieval after conservative surgery.
|
Gynecol Obstet Invest
|
2010
|
0.86
|
|
44
|
Endometrial stromal sarcoma presenting as postpartum haemorrhage: report of a case with a sole t(10;17)(q22;p13) translocation.
|
Gynecol Oncol
|
2003
|
0.85
|
|
45
|
Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer.
|
Gynecol Oncol
|
2003
|
0.85
|
|
46
|
In utero exposure to chemotherapy: effect on cardiac and neurologic outcome.
|
J Clin Oncol
|
2006
|
0.83
|
|
47
|
Randomized, phase II, placebo-controlled, double-blind study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment followed by maintenance treatment in advanced ovarian cancer.
|
J Clin Oncol
|
2013
|
0.82
|
|
48
|
Identification of a novel, recurrent MBTD1-CXorf67 fusion in low-grade endometrial stromal sarcoma.
|
Int J Cancer
|
2013
|
0.82
|
|
49
|
The functional neuroanatomy of multitasking: combining dual tasking with a short term memory task.
|
Neuropsychologia
|
2013
|
0.82
|
|
50
|
Progesterone receptor in estrogen receptor-positive breast cancer: the association between HER-2 and lymph node involvement is age related.
|
J Clin Oncol
|
2006
|
0.81
|
|
51
|
Role of neoadjuvant chemotherapy in the management of stage IIIC-IV ovarian cancer: survey results from the members of the European Society of Gynecological Oncology.
|
Int J Gynecol Cancer
|
2012
|
0.81
|
|
52
|
Neoadjuvant chemotherapy for ovarian cancer.
|
Oncology (Williston Park)
|
2005
|
0.81
|
|
53
|
Synchronous ovarian and endometrial cancer--an international multicenter case-control study.
|
Int J Gynecol Cancer
|
2014
|
0.81
|
|
54
|
Polymorphisms in inflammation pathway genes and endometrial cancer risk.
|
Cancer Epidemiol Biomarkers Prev
|
2012
|
0.81
|
|
55
|
The addition of 4% oxygen to the CO(2) pneumoperitoneum does not decrease dramatically port site metastases.
|
J Minim Invasive Gynecol
|
2008
|
0.81
|
|
56
|
Being Pregnant and Diagnosed with Breast Cancer.
|
Breast Care (Basel)
|
2012
|
0.80
|
|
57
|
In Vitro Validation of Survivin as Target Tumor-associated Antigen for Immunotherapy in Uterine Cancer.
|
J Immunother
|
2015
|
0.80
|
|
58
|
Conditioning of the abdominal cavity reduces tumor implantation in a laparoscopic mouse model.
|
Surg Today
|
2014
|
0.80
|
|
59
|
The use of laser microdissection and SELDI-TOF MS in ovarian cancer tissue to identify protein profiles.
|
Anticancer Res
|
2009
|
0.80
|
|
60
|
Growth differentiation factor-15 as biomarker in uterine sarcomas.
|
Int J Gynecol Cancer
|
2014
|
0.80
|
|
61
|
Breast cancer susceptibility polymorphisms and endometrial cancer risk: a Collaborative Endometrial Cancer Study.
|
Carcinogenesis
|
2011
|
0.79
|
|
62
|
In early-stage breast cancer, the estrogen receptor interacts with correlation between human epidermal growth factor receptor 2 status and age at diagnosis, tumor grade, and lymph node involvement.
|
J Clin Oncol
|
2008
|
0.79
|
|
63
|
Fertility preserving management in gynecologic cancer patients: the need for centralization.
|
Int J Gynecol Cancer
|
2010
|
0.79
|
|
64
|
The management of borderline tumours of the ovary.
|
Curr Opin Oncol
|
2006
|
0.79
|
|
65
|
Neoadjuvant chemotherapy in advanced ovarian cancer: what kind of evidence is needed to convince US gynaecological oncologists?
|
Gynecol Oncol
|
2010
|
0.78
|
|
66
|
Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium.
|
PLoS One
|
2011
|
0.78
|
|
67
|
Value of positron emission tomography of the para-aortic lymph nodes in cervical carcinoma stage IB2-IIIB.
|
J Clin Oncol
|
2008
|
0.78
|
|
68
|
Time to include high-risk early ovarian cancer in randomized phase III trials of advanced ovarian cancer.
|
Gynecol Oncol
|
2006
|
0.78
|
|
69
|
Is it safe to treat endometrial carcinoma endoscopically?
|
J Clin Oncol
|
2009
|
0.78
|
|
70
|
Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study.
|
Int J Gynecol Cancer
|
2009
|
0.78
|
|
71
|
Urachal carcinoma during pregnancy.
|
Urology
|
2006
|
0.77
|
|
72
|
Pelvic exenterations for gynecological malignancies: a study of 36 cases.
|
Int J Gynecol Cancer
|
2012
|
0.77
|
|
73
|
Role of diaphragmatic surgery in 69 patients with ovarian carcinoma.
|
Int J Gynecol Cancer
|
2009
|
0.77
|
|
74
|
The role of diaphragmatic surgery during interval debulking after neoadjuvant chemotherapy: an analysis of 74 patients with advanced epithelial ovarian cancer.
|
Int J Gynecol Cancer
|
2010
|
0.77
|
|
75
|
Application of proteomics in ovarian cancer: which sample should be used?
|
Gynecol Oncol
|
2009
|
0.77
|
|
76
|
The impact of enzastaurin (LY317615.HCl) on CA125 biosynthesis and shedding in ovarian cancer cells.
|
Gynecol Oncol
|
2010
|
0.76
|
|
77
|
Aromatase inhibitors in premenopausal women: the need for proper contraceptive counseling.
|
Breast J
|
2006
|
0.76
|
|
78
|
Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer.
|
Eur J Cancer
|
2012
|
0.76
|
|
79
|
Bilateral Mammary Tuberculosis Associated with a Borderline Ovarian Tumor.
|
Breast Care (Basel)
|
2008
|
0.76
|
|
80
|
Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations.
|
J Transl Med
|
2014
|
0.75
|
|
81
|
Fertility preservation in (breast) cancer patients: is it safe?
|
J Clin Oncol
|
2006
|
0.75
|
|
82
|
Use of chemotherapy during pregnancy in the treatment of ovarian malignancies.
|
Eur J Obstet Gynecol Reprod Biol
|
2011
|
0.75
|
|
83
|
The rationale for comprehensive surgical staging in endometrial carcinosarcoma.
|
Gynecol Oncol
|
2005
|
0.75
|
|
84
|
Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer.
|
Nat Genet
|
2015
|
0.75
|
|
85
|
FISH analysis of PTEN in endometrial carcinoma. Comparison with SNP arrays and MLPA.
|
Histopathology
|
2014
|
0.75
|
|
86
|
Importance of the endometrioid carcinoma subtype and sarcomatous component in uterine carcinosarcoma.
|
Gynecol Oncol
|
2004
|
0.75
|
|
87
|
ESGO statement on the role of CA-125 measurement in follow-up of epithelial ovarian cancer.
|
Int J Gynecol Cancer
|
2012
|
0.75
|
|
88
|
Reproduction rates after cytotoxic therapy.
|
J Clin Oncol
|
2009
|
0.75
|
|
89
|
PTEN mutation analysis in uterine leiomyosarcomas and mixed mullerian sarcomas.
|
Am J Obstet Gynecol
|
2002
|
0.75
|
|
90
|
Successful conservative treatment of endocervical adenocarcinoma stage Ib1 diagnosed early in pregnancy.
|
Acta Obstet Gynecol Scand
|
2008
|
0.75
|
|
91
|
Psycho-oncology: structure and profiles of European centers treating patients with gynecological cancer.
|
Int J Gynecol Cancer
|
2011
|
0.75
|
|
92
|
Staging with Unilateral Salpingo-Oophorectomy and Expert Pathological Review Result in No Recurrences in a Series of 81 Intestinal-Type Mucinous Borderline Ovarian Tumors.
|
Gynecol Obstet Invest
|
2017
|
0.75
|
|
93
|
Training in bowel and upper abdominal surgery in gynaecological oncology: European Society of Gynecological Oncology (ESGO) Statement.
|
Int J Gynecol Cancer
|
2011
|
0.75
|
|
94
|
A Real-Life Analysis of Reproductive Outcome after Fertility Preservation in Female Cancer Patients.
|
Gynecol Obstet Invest
|
2017
|
0.75
|
|
95
|
Breastfeeding a child on treatment for childhood cancer.
|
J Oncol Pharm Pract
|
2013
|
0.75
|
|
96
|
The 13th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2010).
|
Gynecol Oncol
|
2011
|
0.75
|
|
97
|
CD10, estrogen and progesterone receptor expression in ovarian adenosarcoma.
|
Gynecol Oncol
|
2005
|
0.75
|
|
98
|
Comparison of diaphragmatic surgery at primary or interval debulking in advanced ovarian carcinoma: an analysis of 163 patients.
|
Eur J Cancer
|
2010
|
0.75
|